Summary
This webinar will provide an overview of the players, products, and regulatory and legal schemes of the biosimilars market in China and how it compares to the U.S. market.
Speakers
Related Content
- InsightNovember 1, 2024
Four Steps to Maximize the Value of AI Innovation in Medtech
- InsightSeptember 9, 2024
Are AI Inventions Harder to Patent?
- InsightAugust 14, 2024
FDA Platform Technology Draft Guidance Highlights Utility of Obscure Patent Term Extension Provision
- AlertAugust 2, 2024
USPTO Issues Further Guidance on AI-Related Patent Eligibility
- InsightJuly 25, 2024
The Rapid Rise of AI, in Five Charts
- AlertMay 22, 2024
The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims
- AlertMarch 12, 2024
USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences
- AlertFebruary 13, 2024
USPTO Issues New Guidance on Patenting AI-Assisted Inventions
- Speaking EngagementsNovember 12, 2024
US & EP Data Exclusivity: Same Name, Different Games
- Awards and RankingsOctober 30, 2024
Eight Goodwin Partners Named 2025 IAM Global Leaders
- Press ReleaseOctober 29, 2024
Goodwin Advises HLTH in its Acquisition by Hyve
- Press ReleaseOctober 21, 2024
Zip Closes $190 Million Series D, Largest Funding Round in AI-Powered Procurement Orchestration Sector
- Awards and RankingsOctober 17, 2024
Goodwin UK Highly Ranked in Chambers UK 2025
- In the PressOctober 17, 2024
Reliance on Third-Party "Pricing" Facilitators Is Under Increasing Antitrust Scrutiny (Intellectual Property& Technology Law Journal)
- Awards and RankingsOctober 9, 2024
Benchmark Litigation US 2025 Recognizes 45 Goodwin Litigators
- Speaking EngagementsOctober 8, 2024 | 1:15 PM - 2:30 PM ET
ACI's 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA